SURGICAL INNOVATIONS GROUP PLC - Full Year Results

Surgical Innovations Group PLC’s FY2025 investor update highlights resilient company performance amid challenging market conditions, with revenue broadly flat at £11.6m due to headwinds including US tariffs, OEM supply chain constraints, and reduced elective procedures in the UK. Despite this, the Group delivered strong regional growth, particularly in Europe (+23%) and UK third-party sales (+14%), reflecting successful execution of its growth strategy and increasing demand for its sustainability-led product offering. Gross margins improved significantly to ~34%, supported by favorable product mix, pricing initiatives, and ongoing cost reduction programmes, although EBITDA remained negative. The company reported positive operating cash flow (£0.6m) and strengthened its balance sheet through improved working capital management, including inventory reduction and tighter control of receivables and payables. Strategic progress included achieving MDR certification, enhancing regulatory positioning and enabling future product innovation, alongside investment in sales infrastructure, international distribution expansion, and high-margin product focus. Looking ahead, Surgical Innovations is targeting revenue growth and margin expansion through a strengthened order book, new product pipeline, US market development, and operational efficiencies. Management remains focused on driving sustainable profitability, leveraging clinical relationships, and capitalizing on global market opportunities to deliver improved financial results in 2026 and beyond.